1. Adelaide Research & Scholarship
  2. Schools and Disciplines
  3. School of Medicine
  4. Medicine
  5. Medicine publications
Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/138545
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTan, S.-
dc.contributor.authorSpear, E.-
dc.contributor.authorSane, N.-
dc.contributor.authorNelson, A.J.-
dc.contributor.authorNerlekar, N.-
dc.contributor.authorSegelov, E.-
dc.contributor.authorNicholls, S.J.-
dc.date.issued2023-
dc.identifier.citationJournal of Human Hypertension, 2023; 37(11):1043-1046-
dc.identifier.issn0950-9240-
dc.identifier.issn1476-5527-
dc.identifier.urihttps://hdl.handle.net/2440/138545-
dc.descriptionPublished online: 19 April 2023-
dc.description.abstractImmune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.-
dc.description.statementofresponsibilitySean Tan, Ella Spear, Nikhita Sane, Adam J. Nelson, Nitesh Nerlekar, Eva Segelov and Stephen J. Nicholls-
dc.language.isoen-
dc.publisherSpringer-
dc.rights© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http:// creativecommons.org/licenses/by/4.0/.-
dc.source.urihttp://dx.doi.org/10.1038/s41371-023-00831-z-
dc.subjectHumans-
dc.subjectNeoplasms-
dc.subjectHypertension-
dc.subjectBlood Pressure-
dc.subjectAtherosclerosis-
dc.subjectImmune Checkpoint Inhibitors-
dc.titleBlood pressure surveillance in cancer patients treated with immune checkpoint inhibitors-
dc.typeJournal article-
dc.identifier.doi10.1038/s41371-023-00831-z-
dc.relation.grantNHMRC-
pubs.publication-statusPublished-
dc.identifier.orcidNelson, A.J. [0000-0003-0990-2548]-
dc.identifier.orcidNicholls, S.J. [0000-0002-9668-4368]-
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_138545.pdfPublished version328.12 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.